Drugs / BR1015-1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT07421388 Comparator | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07421375 Comparator | Apr → May 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06744062 Comparator | Jan → Mar 2025 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06744127 Comparator | Jan → Mar 2025 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06008015 Comparator | Sep → Oct 2023 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06008028 Comparator | Aug → Oct 2023 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1015-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07421375 ↗ |
| Route | Oral | “Oral Administration” NCT07421375 ↗ |